Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-18 5:26 pm Purchase | 2026-05-14 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | BIOTECHNOLOGY VALUE FUND L P | 7,593,303 43.300% | 5,003,000 (+193.14%) | Filing History |
| 2026-05-15 09:03 am Purchase | 2026-03-31 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | Woodline Partners LP | 640,001 5.400% | 640,001 (New Position) | Filing History |
| 2026-05-01 9:15 pm Purchase | 2026-04-27 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | LIGAND PHARMACEUTICALS INC LGND | 8,062,678 47.000% | 8,062,678 (New Position) | Filing History |
| 2026-04-30 2:38 pm Purchase | 2026-03-31 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | VANGUARD CAPITAL MANAGEMENT LLC | 613,458 5.150% | 613,458 (New Position) | Filing History |
| 2026-04-29 5:43 pm Unchanged | 2026-04-27 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,590,303 21.400% | 0 (Unchanged) | Filing History |
| 2026-04-27 4:12 pm Purchase | 2026-03-31 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | BlackRock, Inc. BLK | 640,549 5.400% | 479,869 (+298.65%) | Filing History |
| 2026-03-27 2:14 pm Sale | 2026-03-13 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | VANGUARD GROUP INC | 0 0.000% | -638,813 (Position Closed) | Filing History |
| 2026-03-06 10:05 am Purchase | 2026-02-27 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | FMR LLC | 1,268,506 10.200% | 188,918 (+17.50%) | Filing History |
| 2026-02-12 2:36 pm Purchase | 2025-12-31 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | Morgan Stanley MS | 1,702,545 13.700% | 177,048 (+11.61%) | Filing History |
| 2025-08-06 12:19 pm Sale | 2025-06-30 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | FMR LLC | 1,079,588 9.000% | -75,445 (-6.53%) | Filing History |
| 2025-07-29 2:54 pm Purchase | 2025-06-30 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | VANGUARD GROUP INC | 638,813 5.330% | 638,813 (New Position) | Filing History |
| 2025-06-06 4:14 pm Purchase | 2025-05-30 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | Morgan Stanley MS | 1,525,497 12.700% | 414,349 (+37.29%) | Filing History |
| 2025-05-20 6:52 pm Sale | 2025-05-16 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,590,303 21.600% | -392,723 (-13.17%) | Filing History |
| 2025-05-07 11:35 am Purchase | 2025-03-31 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | Morgan Stanley MS | 1,111,148 9.300% | 1,111,148 (New Position) | Filing History |
| 2025-01-28 5:19 pm Sale | 2025-01-24 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,983,026 25.300% | -650,717 (-17.91%) | Filing History |
| 2024-02-09 10:05 am Sale | 2024-02-08 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | FMR LLC | 1,155,033 10.054% | -91,653 (-7.35%) | Filing History |
| 2024-01-16 5:22 pm Purchase | 2024-01-11 | 13D | XOMA ROYALTY CORPORATION COMMO XOMA | BIOTECHNOLOGY VALUE FUND L P | 3,633,743 31.600% | 103,200 (+2.92%) | Filing History |
| 2023-02-09 12:46 pm Purchase | 2023-02-09 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | FMR LLC | 1,246,686 10.887% | 83,598 (+7.19%) | Filing History |
| 2022-08-10 08:10 am Purchase | 2022-08-09 | 13G | XOMA ROYALTY CORPORATION COMMO XOMA | FMR LLC | 1,163,088 10.183% | 275,566 (+31.05%) | Filing History |
| 2022-02-14 5:20 pm Sale | 2021-12-31 | 13G | XOMA ROYALTY CRP DEP REPSTG 1/ XOMAO | Eagle Point Credit Management LLC | 0 0.000% | -149,248 (Position Closed) | Filing History |